Stay updated on Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial

Sign up to get notified when there's something new on the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:23:56.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the evaluation of whether 7-day treatment with oral QLT091001 can improve visual function in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to RPE65 or LRAT mutations in a medical study.
    Difference
    0.2%
    Check dated 2024-06-06T14:40:35.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the required health conditions, age ranges, and other inclusion and exclusion factors for participants with LCA or RP. Previously, this section had no information provided.
    Difference
    18%
    Check dated 2024-05-22T21:24:17.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:26:15.000Z thumbnail image

Stay in the know with updates to Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Oral QLT091001 in LCA/RP Due to RPE65/LRAT Mutations Clinical Trial page.